E Fund Management Co. Ltd. Acquires 808 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

E Fund Management Co. Ltd. increased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 21.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,495 shares of the company’s stock after acquiring an additional 808 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Krystal Biotech were worth $558,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its holdings in Krystal Biotech by 111.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock worth $83,000 after acquiring an additional 379 shares during the period. Fox Run Management L.L.C. bought a new stake in shares of Krystal Biotech in the third quarter valued at $219,000. Prime Capital Investment Advisors LLC bought a new stake in shares of Krystal Biotech in the fourth quarter valued at $310,000. Graham Capital Management L.P. bought a new stake in shares of Krystal Biotech in the third quarter valued at $330,000. Finally, Confluence Wealth Services Inc. grew its position in shares of Krystal Biotech by 20.7% in the third quarter. Confluence Wealth Services Inc. now owns 2,920 shares of the company’s stock valued at $339,000 after purchasing an additional 500 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, CAO Kathryn Romano sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the transaction, the chief accounting officer now owns 12,936 shares in the company, valued at approximately $2,145,823.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,087 shares of company stock worth $6,210,591. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Trading Down 2.5 %

Shares of KRYS traded down $4.08 during midday trading on Wednesday, reaching $157.68. The stock had a trading volume of 244,959 shares, compared to its average volume of 363,836. The company’s 50-day moving average is $168.76 and its 200 day moving average is $134.27. Krystal Biotech, Inc. has a 12-month low of $86.03 and a 12-month high of $189.97. The company has a market capitalization of $4.50 billion, a price-to-earnings ratio of 1,971.25 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The firm had revenue of $45.25 million during the quarter, compared to the consensus estimate of $47.37 million. During the same period in the previous year, the business posted ($1.76) earnings per share. The company’s revenue was up 452400.0% compared to the same quarter last year. Research analysts forecast that Krystal Biotech, Inc. will post 1.82 EPS for the current fiscal year.

Analysts Set New Price Targets

KRYS has been the subject of several recent research reports. Stifel Nicolaus reiterated a “buy” rating and issued a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Citigroup boosted their target price on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Guggenheim boosted their target price on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Krystal Biotech in a research report on Monday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Krystal Biotech presently has an average rating of “Buy” and an average price target of $171.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).